Metabolic Research
MOTS-C
MOTS-c is a mitochondrial-derived peptide studied in metabolic signaling and skeletal-muscle adaptation, with experimental interventions supported mainly by cell and animal evidence.
$140USD / vial · 40 mg
Research only Single compound
Retatrutide
Catalog size
$155
USD per vial · 20 mgCatalog price
Research onlyRetatrutide is a synthetic peptide studied for coordinated activation of three metabolic hormone receptors, with human research examining glucose regulation, appetite, body weight and liver fat.
Explore the research profileSubmit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
No reservation or purchase is made by adding a material.
View documentation status ← Back to collection- Material
- Retatrutide
- Format
- Awaiting confirmation
- Batch reports
- Check this size in the COA library
- Availability
- Confirmed during review
Catalog quantities are not assay results.
In the literature
A closer look at the science.
GLP-1, GIP and glucagon receptor agonist
What is Retatrutide?
Retatrutide, also designated LY3437943, combines glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon receptor activity within one molecule. Its discovery program connected receptor assays and obese-mouse experiments with early human pharmacology, providing a framework for studying how several hormonal signals interact.
- Research class
- GLP-1, GIP and glucagon receptor agonist
- Catalog search names
- Reta · GLP-3R
- Literature designation
- LY3437943
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
Mechanisms under investigation
The three receptors influence overlapping aspects of energy and glucose regulation. In the discovery experiments, glucagon receptor signaling contributed increased energy expenditure, while GIP and GLP-1 receptor activity contributed reduced food intake. The relative contribution of each pathway in humans cannot be read directly from the mouse findings.
Documented lines of inquiry
Research areas
- 01
Glucose regulation and appetite
A 40-week phase 3 trial in 537 adults with type 2 diabetes found greater average HbA1c reductions than placebo. HbA1c reflects blood glucose over time. Separate exploratory phase 2 questionnaires found reduced reported hunger and appetite in several study groups. Those self-reports do not directly measure food intake or isolate each receptor’s contribution. [4][5]
- 02
Body-weight outcomes
A randomized phase 2 study involving 338 adults with obesity or overweight and associated conditions found larger average weight reductions with retatrutide than placebo. Gastrointestinal events and changes in heart rate were among the findings tracked alongside efficacy. [2]
- 03
Liver-fat measurement
A 98-participant substudy examined people with elevated liver fat using imaging-based measurements. Liver-fat reductions accompanied broader metabolic changes. An imaging endpoint is distinct from proving fibrosis reversal or preventing liver-related clinical events. [3]
Study topics describe the cited models, not established benefits of this catalog material.
Reading the evidenceWhat the studies
Human trials with supporting preclinical pharmacology
What the studies
can tell us.
Human trials with supporting preclinical pharmacologyThe cited studies include randomized trials of weight and glucose endpoints, a liver-fat imaging substudy and exploratory appetite questionnaires. They support several lines of metabolic inquiry, with experimental receptor studies providing mechanistic context. Results remain specific to the participants, study formulations and measurements; changes in appetite scores are distinct from measured food intake or long-term health outcomes.
What remains uncertain
Trial averages conceal individual variation, and the cited studies alone do not resolve long-term outcomes or rare harms. Sponsor involvement should be considered when evaluating the evidence. Findings from clinical formulations do not establish the identity, quality, safety or equivalence of WYZ research materials.
Read the source
Selected literature
Primary studies and clearly identified supporting sources. Each link opens the original record.
- 01PubMed
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss… (opens a new tab)
Discovery pharmacology, mouse metabolism and early human exposure; title abbreviated.
- 02PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (opens a new tab)
Randomized obesity trial with weight, tolerability and heart-rate outcomes.
- 03PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (opens a new tab)
Liver-fat imaging substudy; not a fibrosis-outcome trial.
- 04PubMed
Efficacy and safety of retatrutide… in people with type 2 diabetes… (TRANSCEND-T2D-1) (opens a new tab)
Published June 2026; randomized phase 3 trial in 537 adults, measuring HbA1c, weight and adverse events; title abbreviated.
- 05PubMed
Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study (opens a new tab)
Prespecified questionnaire analyses in 275 adults; reported hunger and eating behavior, not direct food-intake measurements.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Before you begin
The details behind
the material.
Specifications and storage
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
Research use only
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COAContinue exploring.
All materialsOther single compounds in the collection.
View details
Dermal Research
GHK-Cu
GHK-Cu is a copper complex of glycyl-histidyl-lysine studied for its effects on extracellular-matrix production and remodeling in experimental tissue-repair systems.
$50USD / vial · 50 mg
Research only
Secretagogue Research
Tesamorelin
Tesamorelin is a stabilized GHRH analogue studied for changes in visceral and liver fat, principally in people with HIV-associated abdominal adiposity.
$80USD / vial · 10 mg
Research only